| Literature DB >> 27460348 |
Valérie Decostre1, Pascal Laforêt2, Aleksandra Nadaj-Pakleza3, Marie De Antonio4, Sylvain Leveugle4, Gwenn Ollivier5, Aurélie Canal5, Kahina Kachetel6, François Petit7, Bruno Eymard6, Anthony Behin6, Karim Wahbi8, Philippe Labrune9, Jean-Yves Hogrel5.
Abstract
Glycogen storage disease type III is an inherited metabolic disorder characterized by liver and muscle impairment. This study aimed to identify promising muscle function measures for future studies on natural disease progression and therapeutic trials. The age-effect on the manual muscle testing (MMT), the hand-held dynamometry (HHD), the motor function measure (MFM) and the Purdue pegboard test was evaluated by regression analysis in a cross-sectional retrospective single site study. In patients aged between 13 and 56 years old, the Purdue pegboard test and dynamometry of key pinch and knee extension strength were age-sensitive with annual losses of 1.49, 1.10 and 0.70% of the predicted values (%pred), respectively. The MFM score and handgrip strength were also age-sensitive but only in patients older than 29 and 37 years old with annual losses of 1.42 and 1.84%pred, respectively. Muscle strength assessed by MMT and elbow extension measured by HHD demonstrated an annual loss of less than 0.50%pred and are thus unlikely to be promising outcome measures for future clinical trials. In conclusion, our results identified age-sensitive outcomes from retrospective data and may serve for future longitudinal studies in which an estimation of the minimal number of subjects is provided.Entities:
Keywords: Debranching enzyme deficiency; Glycogen storage disease type III; Metabolic myopathy; Outcome measures
Mesh:
Year: 2016 PMID: 27460348 DOI: 10.1016/j.nmd.2016.06.460
Source DB: PubMed Journal: Neuromuscul Disord ISSN: 0960-8966 Impact factor: 4.296